FAP-Targeted SPECT/CT and PET/CT Imaging for Breast Cancer Patients.
review · Level V
Where this comes from
- Record sourced from PubMed, PMID 39780367.
- Also identified by DOI 10.1097/RLU.0000000000005617.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Breast cancer presents a significant global health challenge, necessitating continued innovation in diagnostic and therapeutic approaches. Recent advances have led to the identification of cancer-associated fibroblasts, which are highly prevalent in breast cancers and express fibroblast activation proteins (FAPs), as critical targets. FAP-specific radiotracers, when used with PET/CT and SPECT/CT, have significant potential for improving early breast cancer detection, staging, treatment response monitoring, and therapeutic intervention. This review provides insight into FAP-targeted molecular imaging, exploring advanced techniques for protein status assessment, development of early-phase targeted therapies, and other emerging applications. The advent of FAP-targeted imaging stands to significantly enhance personalized oncologic care, leading to improved breast cancer management and overall patient outcomes.
Medical subject headings
- Breast Neoplasms
- Positron Emission Tomography Computed Tomography
- Serine Endopeptidases
- Membrane Proteins
- Gelatinases
- Single Photon Emission Computed Tomography Computed Tomography